Breast Cancer associated with carriage of a mutation СНЕК2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents clinical cases in which the patients were diagnosed with breast cancer (BC) associated with mutations in the CHEK2 gene. Objective. To investigate the characteristics of treatment and prevention in patients with BC associated with СНЕК2 mutation carriage. Subjects and methods. In 2016-2017, the P.A. Herzen Moscow Oncology Research Institute treated three patients diagnosed with BC associated with CHEK2 mutation carriage. Two cases underwent preventive surgery: prophylactic subcutaneous mastectomy with single-stage reconstruction in one case and prophylactic bilateral tubo-ovariectomy in the other. A further follow-up of these patients and their relatives will be able to draw conclusions about the correctness of preventive surgery policy. Results. In all the three clinical cases, the patients were diagnosed with germline missense I157T mutation (p.I1e157Thr) in exon 3 of the CHEK 2 gene, which results in amino acid substitution (isoleucine to threonine at codon 470 - c.470T>C) in a heterozygous state. The volume of surgical interventions for BC, preventive surgery on the breast and ovaries in our patients was decided individually based on their clinical data. Genetic examination of their relatives is needed for primary prevention of BC. Conclusion. There is a need for further investigations in patients with BRCA1, 2, CHEK 2 mutations, as there will be a growing number of patients with mutations in these genes due to a larger number of genetic laboratories. Knowing the characteristics of inheritance and development of hereditary BC, it is necessary to elaborate surgical treatment policy for these patients, algorithms for follow-up of the patients, and an algorithm for examination and prevention of BC among their relatives.

Full Text

Restricted Access

About the authors

Andrei D. Kaprin

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia; Peoples' Friendship University of Russia, Ministry of Education and Science of Russia

Email: Kaprin@yandex.ru
corresponding member of the Russian Academy of Sciences, Director

Andrey A. Kostin

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia; Peoples' Friendship University of Russia, Ministry of Education and Science of Russia

Email: andocrey@mail.ru
MD, Deputy Director

Aziz D. Styracaceae

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia; Peoples' Friendship University of Russia, Ministry of Education and Science of Russia

Email: azizz@mail.ru
PhD, MD, Professor of the Department of Oncology and Radiology; Head of the Department of Oncology and Reconstructive Surgery of the Mammary Gland and Skin

Elena A. Rasskazova

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia

Email: Rasskaz2@yandex.ru
PhD, researcher of the Department of Oncology and Reconstructive Surgery of the Mammary Gland and Skin

Irina M. Shirokikh

Peoples' Friendship University of Russia, Ministry of Education and Science of Russia

Email: shirokikh-irinal@yandex.ru
post-graduate student of the Department of Oncology and radiology

References

  1. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2016 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2017. 236с.
  2. Бит-Сава Е.М. Молекулярно-биологическое обоснование лечения BRCA1 /СНЕК2/BLM-ассоциированного и спорадического рака молочной железы: дисс. д-ра мед. наук. СПб.; 2015.
  3. Громыко О.Е. Диагностика полиморфизма гена ТПМТ и наследственных мутаций в генах ВRСА1,2 и СНЕК2: автореф. дисс. канд. мед. наук. М.; 2008.
  4. Батенева Е.И., Филиппова М.Г., Тюляндина А. С., Мещеряков А.А., Жорданиа К.И., Грицай А.Н., Кадочникова В.В., Абрамов Д.Д., Рагимов А.А., Трофимов Д.Ю., Любченко Л.Н. Высокая частота мутаций в генах BRCA1, BRCA2, CHEK2, NBN, BLM у больных раком яичников в Российской популяции. Опухоли женской репродуктивной системы. 2014; 4: 51-6.
  5. Бессонов А.А., Иевлева А.Г., Имянитов Е.Н., Соколенко А.П. Наследственный рак молочной железы, ассоциированный с мутациями в гене CHEK2. Вопросы онкологии. 2016; 62(6): 754-7.
  6. Adank M.A., Jonker M.A., Kluijt I., van Mil S.E., Oldenburg R.A., Mooi WJ. et al. CHEK2* 1100delC homozygosity is associated with breast cancer risk in women. J. Med. Genet. 2011; 48(12): 860-3
  7. Cybulski C., Wokolorczyk D., Jakubowska A., Huzarski T., Byrski T., Gronwald J. et al. Risk of breast cancer in women with a' CHEK2 mutation with and without a family history of breast cancer. J. Clin. Oncol. 2011; 29(28): 3747-52.
  8. Рагулин Ю.А., Афонин Г.В., Аминов Г.Г., Сидорин А.В. Органосохраняющее лечение первично-диссемированного рака молочной железы с метахронным билатеральным поражением. Опухоли женской репродуктивной системы. 2016; 12(1): 63-7.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies